The global market for Lung Cancer Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Lung Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Lung Cancer Therapeutics by region & country, by Type, and by Application.

The Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Therapeutics.

Market Segmentation

Scope of Lung Cancer Therapeutics - Market Report

Report Metric	Details
Report Name	Lung Cancer Therapeutics - Market
CAGR	5%
Segment by Type:	Targeted Therapy Immunotherapy Chemotherapy Radiation Therapy Others
Segment by Application	Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Roche, Boehringer Ingelheim GmbH, Pfizer, Sanofi S.A., Bristol-Myers Squibb, Novartis, Agennix AG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Lung Cancer Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Lung Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Lung Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Lung Cancer Therapeutics - Market report?

Ans: The main players in the Lung Cancer Therapeutics - Market are AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Roche, Boehringer Ingelheim GmbH, Pfizer, Sanofi S.A., Bristol-Myers Squibb, Novartis, Agennix AG

What are the Application segmentation covered in the Lung Cancer Therapeutics - Market report?

Ans: The Applications covered in the Lung Cancer Therapeutics - Market report are Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

What are the Type segmentation covered in the Lung Cancer Therapeutics - Market report?

Ans: The Types covered in the Lung Cancer Therapeutics - Market report are Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Others

1 Market Overview

1.1 Lung Cancer Therapeutics Product Introduction

1.2 Global Lung Cancer Therapeutics Market Size Forecast

1.3 Lung Cancer Therapeutics Market Trends & Drivers

1.3.1 Lung Cancer Therapeutics Industry Trends

1.3.2 Lung Cancer Therapeutics Market Drivers & Opportunity

1.3.3 Lung Cancer Therapeutics Market Challenges

1.3.4 Lung Cancer Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Lung Cancer Therapeutics Players Revenue Ranking (2023)

2.2 Global Lung Cancer Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Lung Cancer Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Lung Cancer Therapeutics

2.6 Lung Cancer Therapeutics Market Competitive Analysis

2.6.1 Lung Cancer Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Lung Cancer Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Targeted Therapy

3.1.2 Immunotherapy

3.1.3 Chemotherapy

3.1.4 Radiation Therapy

3.1.5 Others

3.2 Global Lung Cancer Therapeutics Sales Value by Type

3.2.1 Global Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Lung Cancer Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Lung Cancer Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Non-Small Cell Lung Cancer (NSCLC)

4.1.2 Small Cell Lung Cancer (SCLC)

4.2 Global Lung Cancer Therapeutics Sales Value by Application

4.2.1 Global Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Lung Cancer Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Lung Cancer Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Lung Cancer Therapeutics Sales Value by Region

5.1.1 Global Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Lung Cancer Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Lung Cancer Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Lung Cancer Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Lung Cancer Therapeutics Sales Value, 2019-2030

5.2.2 North America Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Lung Cancer Therapeutics Sales Value, 2019-2030

5.3.2 Europe Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Lung Cancer Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Lung Cancer Therapeutics Sales Value, 2019-2030

5.5.2 South America Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Lung Cancer Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Lung Cancer Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Lung Cancer Therapeutics Sales Value

6.3 United States

6.3.1 United States Lung Cancer Therapeutics Sales Value, 2019-2030

6.3.2 United States Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Lung Cancer Therapeutics Sales Value, 2019-2030

6.4.2 Europe Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Lung Cancer Therapeutics Sales Value, 2019-2030

6.5.2 China Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Lung Cancer Therapeutics Sales Value, 2019-2030

6.6.2 Japan Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Lung Cancer Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Lung Cancer Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Lung Cancer Therapeutics Sales Value, 2019-2030

6.9.2 India Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Lung Cancer Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 AstraZeneca

7.1.1 AstraZeneca Profile

7.1.2 AstraZeneca Main Business

7.1.3 AstraZeneca Lung Cancer Therapeutics Products, Services and Solutions

7.1.4 AstraZeneca Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 AstraZeneca Recent Developments

7.2 Eli Lilly and Company

7.2.1 Eli Lilly and Company Profile

7.2.2 Eli Lilly and Company Main Business

7.2.3 Eli Lilly and Company Lung Cancer Therapeutics Products, Services and Solutions

7.2.4 Eli Lilly and Company Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Eli Lilly and Company Recent Developments

7.3 GlaxoSmithKline

7.3.1 GlaxoSmithKline Profile

7.3.2 GlaxoSmithKline Main Business

7.3.3 GlaxoSmithKline Lung Cancer Therapeutics Products, Services and Solutions

7.3.4 GlaxoSmithKline Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 Roche Recent Developments

7.4 Roche

7.4.1 Roche Profile

7.4.2 Roche Main Business

7.4.3 Roche Lung Cancer Therapeutics Products, Services and Solutions

7.4.4 Roche Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 Roche Recent Developments

7.5 Boehringer Ingelheim GmbH

7.5.1 Boehringer Ingelheim GmbH Profile

7.5.2 Boehringer Ingelheim GmbH Main Business

7.5.3 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Products, Services and Solutions

7.5.4 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Boehringer Ingelheim GmbH Recent Developments

7.6 Pfizer

7.6.1 Pfizer Profile

7.6.2 Pfizer Main Business

7.6.3 Pfizer Lung Cancer Therapeutics Products, Services and Solutions

7.6.4 Pfizer Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Pfizer Recent Developments

7.7 Sanofi S.A.

7.7.1 Sanofi S.A. Profile

7.7.2 Sanofi S.A. Main Business

7.7.3 Sanofi S.A. Lung Cancer Therapeutics Products, Services and Solutions

7.7.4 Sanofi S.A. Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Sanofi S.A. Recent Developments

7.8 Bristol-Myers Squibb

7.8.1 Bristol-Myers Squibb Profile

7.8.2 Bristol-Myers Squibb Main Business

7.8.3 Bristol-Myers Squibb Lung Cancer Therapeutics Products, Services and Solutions

7.8.4 Bristol-Myers Squibb Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Bristol-Myers Squibb Recent Developments

7.9 Novartis

7.9.1 Novartis Profile

7.9.2 Novartis Main Business

7.9.3 Novartis Lung Cancer Therapeutics Products, Services and Solutions

7.9.4 Novartis Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Novartis Recent Developments

7.10 Agennix AG

7.10.1 Agennix AG Profile

7.10.2 Agennix AG Main Business

7.10.3 Agennix AG Lung Cancer Therapeutics Products, Services and Solutions

7.10.4 Agennix AG Lung Cancer Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Agennix AG Recent Developments

8 Industry Chain Analysis

8.1 Lung Cancer Therapeutics Industrial Chain

8.2 Lung Cancer Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Lung Cancer Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Lung Cancer Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Eli Lilly and Company

GlaxoSmithKline PLC

Roche

Boehringer Ingelheim GmbH

List of Tables

Table 1. Lung Cancer Therapeutics Market Trends

Table 2. Lung Cancer Therapeutics Market Drivers & Opportunity

Table 3. Lung Cancer Therapeutics Market Challenges

Table 4. Lung Cancer Therapeutics Market Restraints

Table 5. Global Lung Cancer Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Lung Cancer Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Lung Cancer Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Lung Cancer Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Lung Cancer Therapeutics

Table 10. Global Lung Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Lung Cancer Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Lung Cancer Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Lung Cancer Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Lung Cancer Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Lung Cancer Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Lung Cancer Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Lung Cancer Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Lung Cancer Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Lung Cancer Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Lung Cancer Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Lung Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Lung Cancer Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Lung Cancer Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Lung Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Lung Cancer Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Lung Cancer Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. AstraZeneca Basic Information List

Table 32. AstraZeneca Description and Business Overview

Table 33. AstraZeneca Lung Cancer Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Lung Cancer Therapeutics Business of AstraZeneca (2019-2024)

Table 35. AstraZeneca Recent Developments

Table 36. Eli Lilly and Company Basic Information List

Table 37. Eli Lilly and Company Description and Business Overview

Table 38. Eli Lilly and Company Lung Cancer Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Eli Lilly and Company (2019-2024)

Table 40. Eli Lilly and Company Recent Developments

Table 41. GlaxoSmithKline Basic Information List

Table 42. GlaxoSmithKline Description and Business Overview

Table 43. GlaxoSmithKline Lung Cancer Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Lung Cancer Therapeutics Business of GlaxoSmithKline (2019-2024)

Table 45. GlaxoSmithKline Recent Developments

Table 46. Roche Basic Information List

Table 47. Roche Description and Business Overview

Table 48. Roche Lung Cancer Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Roche (2019-2024)

Table 50. Roche Recent Developments

Table 51. Boehringer Ingelheim GmbH Basic Information List

Table 52. Boehringer Ingelheim GmbH Description and Business Overview

Table 53. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Boehringer Ingelheim GmbH (2019-2024)

Table 55. Boehringer Ingelheim GmbH Recent Developments

Table 56. Pfizer Basic Information List

Table 57. Pfizer Description and Business Overview

Table 58. Pfizer Lung Cancer Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Pfizer (2019-2024)

Table 60. Pfizer Recent Developments

Table 61. Sanofi S.A. Basic Information List

Table 62. Sanofi S.A. Description and Business Overview

Table 63. Sanofi S.A. Lung Cancer Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Sanofi S.A. (2019-2024)

Table 65. Sanofi S.A. Recent Developments

Table 66. Bristol-Myers Squibb Basic Information List

Table 67. Bristol-Myers Squibb Description and Business Overview

Table 68. Bristol-Myers Squibb Lung Cancer Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Bristol-Myers Squibb (2019-2024)

Table 70. Bristol-Myers Squibb Recent Developments

Table 71. Novartis Basic Information List

Table 72. Novartis Description and Business Overview

Table 73. Novartis Lung Cancer Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Novartis (2019-2024)

Table 75. Novartis Recent Developments

Table 76. Agennix AG Basic Information List

Table 77. Agennix AG Description and Business Overview

Table 78. Agennix AG Lung Cancer Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Lung Cancer Therapeutics Business of Agennix AG (2019-2024)

Table 80. Agennix AG Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Lung Cancer Therapeutics Downstream Customers

Table 84. Lung Cancer Therapeutics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Lung Cancer Therapeutics Product Picture

Figure 2. Global Lung Cancer Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Lung Cancer Therapeutics Report Years Considered

Figure 5. Global Lung Cancer Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Lung Cancer Therapeutics Revenue in 2023

Figure 7. Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Targeted Therapy Picture

Figure 9. Immunotherapy Picture

Figure 10. Chemotherapy Picture

Figure 11. Radiation Therapy Picture

Figure 12. Others Picture

Figure 13. Global Lung Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Lung Cancer Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Non-Small Cell Lung Cancer (NSCLC)

Figure 16. Product Picture of Small Cell Lung Cancer (SCLC)

Figure 17. Global Lung Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Lung Cancer Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Lung Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Lung Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Lung Cancer Therapeutics Sales Value (%), (2019-2030)

Figure 30. United States Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 36. China Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 38. China Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 48. India Lung Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Lung Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 50. India Lung Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 51. Lung Cancer Therapeutics Industrial Chain

Figure 52. Lung Cancer Therapeutics Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions